GENELUX Corp
GENELUX Corp (GNLX): 6 pipeline candidates · 2 upcoming catalysts · ~13 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.6 months
D/E 0.41 · 0% dilution
Lead: Phase 3
6 candidates
2 upcoming, next in ~105d
0 buys · 12 sells (180d)
A transparent, data-derived signal for GENELUX Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$127.8M
Cash
$9.3M
Quarterly Burn
$6.1M
Runway
12.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| gl-onc1 | Phase 1 |
| non-platinum chemotherapy | Phase 3 |
| olvi-vec | Phase 1/Phase 2 |
| olvimulogene nanivacirepvec | Phase 2 |
| platinum chemotherapy | Phase 2 |
| v2act immunotherapy | Phase 1/Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
69
Total value held
$23.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,390,960 | $8.2M |
| woodward diversified capital, llc | 2,117,183 | $5.9M |
| geode capital management, llc | 453,761 | $1.1M |
| blackrock, inc. | 405,872 | $982K |
| bank of america corp /de/ | 323,865 | $784K |
| flputnam investment management co | 280,904 | $680K |
| vanguard fiduciary trust co | 251,610 | $609K |
| northern trust corp | 164,456 | $398K |
| provident wealth management, llc | 155,670 | $377K |
| state street corp | 145,850 | $353K |
Showing top 10 of 69 institutional holders of GENELUX Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GENELUX Corp's pipeline?
GENELUX Corp (GNLX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GENELUX Corp's lead drug candidate?
GENELUX Corp's most advanced tracked candidate is gl-onc1 (Phase 1) for Peritoneal Carcinomatosis; Advanced Cancers (Solid Tumors).
What is GENELUX Corp's next catalyst?
GENELUX Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-double" — expected October 1, 2026.
What is GENELUX Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GENELUX Corp has approximately 12.6 months of cash runway.
What is GENELUX Corp's market capitalization?
GENELUX Corp's market capitalization is approximately $127.8M.
Get the full picture on GENELUX Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.